Anti‑Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor

Zhang,Tiansong; Deng,Linhao; Xiong,Qian; Su,Shujun; Gu,Jian

doi:10.3892/ol.2018.8985

Anti‑Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor

Authors:
- Tiansong Zhang
- Linhao Deng
- Qian Xiong
- Shujun Su
- Jian Gu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510623, P.R. China, Department of Obstetrics and Gynecology, Jieyang People's Hospital, Jieyang, Guangdong 522000, P.R. China, Department of Gynecology, The Third Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: June 18, 2018 https://doi.org/10.3892/ol.2018.8985
Pages: 3260-3266

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti‑Müllerian hormone (AMH) has been demonstrated to exhibit an inhibitory effect on the proliferation, invasion, metastasis and drug resistance of ovarian cancer. However, the mechanisms underlying these effects remain unclear. In the present study, 10 µg/ml recombinant human AMH (rhAMH) was administered to human OVCAR3 and OVCAR8 epithelial ovarian cancer (EOC) cell lines. Cell proliferation, apoptosis and cell cycle were analyzed. The level of stem cell factor (SCF) was detected using a reverse transcription‑quantitative polymerase chain reaction and an ELISA, respectively. The exogenous addition of rhAMH signiﬁcantly reduced the proliferation of OVCAR3 and OVCAR8 cell lines compared with the control group (P<0.01). The apoptosis rate in the rhAMH treated group (48 h) significantly increased compared with in the control group (OVCAR3, P=0.035; OVCAR8, P=0.020). The apoptosis rate increased at 72 h but did not exhibit a significant difference when compared with the 48 h group (OVCAR3, P=0.145; OVCAR8, P=0.296). The percentage of cells in the G1 phase in the rhAMH treated group (48 h) increased but was not significantly different compared with the control group (OVCAR3, P=0.070; OVCAR8, P=0.051). However, there was a significant difference at 72 h compared with the control group (OVCAR3, P=0.016; OVCAR8, P=0.019). At 48 h, the rhAMH‑treated group exhibited a statistically significant inhibition of SCF mRNA expression levels (P=0.008), but no significant difference in the protein expression levels (P=0.101) compared with the control, though a significant inhibition was exhibited at 72 h (mRNA expression levels, P=0.005; protein expression levels, P=0.036). The present study revealed that rhAMH may be able to inhibit the proliferation and induce the apoptosis of EOC cells via G1/S‑phase cell cycle arrest and the decreased secretion of SCF.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Lowe KA, Chia VM, Taylor A, O'Malley C, Kelsh M, Mohamed M, Mowat FS and Goff B: An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
3	Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA and Themmen AP: Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 142:4891–4899. 2001. View Article : Google Scholar : PubMed/NCBI
4	Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA and Themmen AP: Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 140:5789–5796. 1999. View Article : Google Scholar : PubMed/NCBI
5	Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, et al: Human ovarian cancer, cell lines, and primary ascites cells express the human Müllerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res. 5:3488–3499. 1999.PubMed/NCBI
6	Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP and MacLaughlin DT: Highly purified Müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res. 8:2640–2646. 2002.PubMed/NCBI
7	Meirelles K, Benedict LA, Dombkowski D, Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, MacLaughlin DT, Donahoe PK and Wei X: Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Müllerian inhibiting substance. Proc Natl Acad Sci USA. 109:2358–2363. 2012. View Article : Google Scholar : PubMed/NCBI
8	Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR, Teixeira J, MacLaughlin DT and Donahoe PK: Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA. 107:18874–18879. 2010. View Article : Google Scholar : PubMed/NCBI
9	Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT and Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Müllerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA. 103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
10	Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF and MacLaughlin DT: Recombinant human Müllerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res. 12:1593–1598. 2006. View Article : Google Scholar : PubMed/NCBI
11	Liang J, Wu YL, Chen BJ, Zhang W, Tanaka Y and Sugiyama H: The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci. 9:435–443. 2013. View Article : Google Scholar : PubMed/NCBI
12	Tonary AM, Macdonald EA, Faught W, Senterman MK and Vanderhyden BC: Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer. 89:242–250. 2000. View Article : Google Scholar : PubMed/NCBI
13	Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE and Alberts DS: Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol. 36:242–249. 2005. View Article : Google Scholar : PubMed/NCBI
14	Arber DA, Tamayo R and Weiss LM: Paraffin section detection of the c-kit gene product (CD117) in human tissues: Value in the diagnosis of mast cell disorders. Hum Pathol. 29:498–504. 1998. View Article : Google Scholar : PubMed/NCBI
15	Hu R, Wang FM, Yu L, Luo Y, Wu X, Li J, Zhang XM, Oehninger S and Bocca S: Antimüllerian hormone regulates stem cell factor expression in human granulosa cells. Fertil Steril. 102:1742–1750.e1. 2014. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Magee JA, Piskounova E and Morrison SJ: Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell. 21:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
18	Foster R, Buckanovich RJ and Rueda BR: Ovarian cancer stem cells: Working towards the root of stemness. Cancer Lett. 338:147–157. 2013. View Article : Google Scholar : PubMed/NCBI
19	Anttonen M, Färkkilä A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, Bützow R and Heikinheimo M: Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Lab Invest. 91:1605–1614. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK and Maheswaran S: Müllerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem. 275:37101–37109. 2000. View Article : Google Scholar : PubMed/NCBI
21	Nilsson E, Rogers N and Skinner MK: Actions of anti-Müllerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition. Reproduction. 134:209–221. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhang W, Stoica G, Tasca SI, Kelly KA and Meininger CJ: Modulation of tumor angiogenesis by stem cell factor. Cancer Res. 60:6757–6762. 2000.PubMed/NCBI
23	Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H and Feng ZH: SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 112:1269–1279. 2008. View Article : Google Scholar : PubMed/NCBI
24	Liu J, Zhang Y, Zhao J, Yang Z, Li D, Katirai F and Huang B: Mast cell: Insight into remodeling a tumor microenvironment. Cancer Metastasis Rev. 30:177–184. 2011. View Article : Google Scholar : PubMed/NCBI
25	Shaw TJ and Vanderhyden BC: AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Gynecol Oncol. 105:122–131. 2007. View Article : Google Scholar : PubMed/NCBI
26	Jung YS, Kim HJ, Seo SK, Choi YS, Nam EJ, Kim S, Kim SW, Han HD, Kim JW and Kim YT: Anti-proliferative and apoptotic activities of Müllerian inhibiting substance combined with calcitriol in ovarian cancer cell lines. Yonsei Med J. 57:33–40. 2016. View Article : Google Scholar : PubMed/NCBI
27	Katiyar S, Jiao X, Wagner E, Lisanti MP and Pestell RG: Somatic excision demonstrates that c-Jun induces cellular migration and invasion through induction of stem cell factor. Mol Cell Biol. 27:1356–1369. 2007. View Article : Google Scholar : PubMed/NCBI
28	Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S and Donahoe PK: Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA. 100:15601–15606. 2003. View Article : Google Scholar : PubMed/NCBI
29	Kano M, Sosulski AE, Zhang L, Saatcioglu HD, Wang D, Nagykery N, Sabatini ME, Gao G, Donahoe PK and Pépin D: AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci USA. 114:E1688–E1697. 2017. View Article : Google Scholar : PubMed/NCBI
30	Park SH, Chung YJ, Song JY, Kim SI, Pépin D, MacLaughlin DT, Donahoe PK and Kim JH: Müllerian inhibiting substance inhibits an ovarian cancer cell line via β-catenin interacting protein deregulation of the Wnt signal pathway. Int J Oncol. 50:1022–1028. 2017. View Article : Google Scholar : PubMed/NCBI
31	Chang HL, Pieretti-Vanmarcke R, Nicolaou F, Li X, Wei X, MacLaughlin DT and Donahoe PK: Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol Oncol. 120:128–134. 2011. View Article : Google Scholar : PubMed/NCBI